Chemotherapy, Radiation Therapy, and Vaccine Therapy With Basiliximab in Treating Patients With Glioblastoma Multiforme That Has Been Removed by Surgery

DISEASE CHARACTERISTICS:

* Histopathologic diagnosis of WHO grade III or WHO grade IV high grade glioma

  * Newly diagnosed disease
* Meets the following criteria:

  * The patient must undergo leukapheresis for immunologic monitoring
* Tumor expression of EGFRvIII by immunohistochemistry (IHC) or polymerase chain reaction (PCR)
* No radiographic or cytologic evidence of leptomeningeal or multicentric disease

PATIENT CHARACTERISTICS:

* Karnofsky performance status ≥ 80%
* Curran Group status of I-IV
* Not pregnant or nursing
* Negative pregnancy test
* Fertile patients must use effective contraception
* No conditions that will potentially confound the study results, including any of the following:

  * Active infection requiring treatment or an unexplained febrile (\> 101.5°F) illness
  * Known immunosuppressive disease or known HIV infection
  * Unstable or severe intercurrent medical conditions such as severe heart or lung disease
* No demonstrated allergy to TMZ
* Able to tolerate TMZ

  * TMZ-induced lymphopenia allowed
* No prior allergic reaction to daclizumab/basiliximab or its components

PRIOR CONCURRENT THERAPY:

* See Disease Characteristics
* No other conventional therapeutic intervention other than steroids, radiation, or temozolomide (TMZ) prior to enrollment
* No prior allogeneic solid organ transplantation
* No prior inguinal lymph node dissection, radiosurgery, brachytherapy, or radiolabeled monoclonal antibodies
* No corticosteroids at a dose above physiologic level except nasal or inhaled steroid at the time of first study vaccination

  * For the purposes of this study, physiologic dose is defined as \< 2 mg of dexamethasone/day
  * Once study vaccinations have been initiated, if patients subsequently require increased steroids, they are permitted to remain on the study
* No prior daclizumab/basiliximab